Search

Your search keyword '"Khaitov, Musa"' showing total 13 results
Start Over Author "Khaitov, Musa" Publisher elsevier b.v.
13 results on '"Khaitov, Musa"'

5. ARIA Phase 4 (2018): change management in allergic rhinitis and asthma multimorbidity using mobile technology

Author

Bousquet, J., Hellings, Peter W., Agache, Ioana, Amat, F., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Bachert, C., Bateman, Eric D., Bedbrook, A., Bennoor, Kazi S., Bewick, M., Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia Z., Bosse, Isabelle, Brozek, Jan, Brussino, Luisa, Canonica, Giorgio W., Cardona, Victòria, Casale, Thomas, Cepeda Sarabia, Alfonso M., Chavannes, Niels H., Cecchi, Lorenzo, Correia de Sousa, Jaime, Costa, Elisio, Cruz, A. A., Czarlewski, Wienczyslawa, De Carlo, Giuseppe, De Feo, G., Demoly, Pascal, Devillier, P., Dykewicz, Mark S., El-Gamal, Yehia, Eller, Esben, Fonseca, J., Fontaine, J. F., Fokkens, W. J., Guzmán, Maria-Antonieta, Haahtela, Tari, Illario, Magdalena, Ivancevich, Juan-Carlos, Just, Jocelyne, Kaidashev, Igor, Khaitov, Musa, and Hourihane, Jonathan O'B.

Subjects
animal structures, ARIA, Change management, Asthma, Rhinitis
Abstract

Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best approach to integrated care pathways (ICPs) using mobile technology in AR and asthma multimorbidity. The proposed next phase of ARIA is Change Management (CM) with the aim of providing an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle whatever their gender or socio-economic status in order to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the impact of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of IT evidence-based tools (MASK: Mobile Airways Sentinel Network) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional.

Published
2018

13. Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results.

Author

Petrova, Nataliia V., Emelyanova, Alexandra G., Gorbunov, Evgeniy A., Edwards, Michael R., Walton, Ross P., Bartlett, Nathan W., Aniscenko, Julia, Gogsadze, Leila, Bakhsoliani, Eteri, Khaitov, Musa R., Johnston, Sebastian L., Tarasov, Sergey A., and Epstein, Oleg I.

Subjects
*COMMON cold, *RHINOVIRUSES, *RESPIRATORY diseases, *OBSTRUCTIVE lung diseases, *ASTHMA, *OLIGOADENYLATE synthetase, *CYTOKINES, *INTERLEUKINS
Abstract

Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have assessed the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the active pharmaceutical ingredients) in in vitro and in vivo experimental models, in order to evaluate their anti-rhinoviral and immunomodulatory potential. HeLa cells were pretreated with AC, and levels of the interferon-stimulated gene (ISG), 2′-5′-oligoadenylate synthetase 1 (OAS1-A) and viral replication were analyzed. In a mouse model of RV-induced exacerbation of allergic airway inflammation we administered Ergoferon and analyzed its effect on type I (IFN-β), type II (IFN-γ) and type III (IFN-λ) IFNs induction, cell counts in bronchoalveolar lavage (BAL), cytokine (interleukin (IL)-4; IL-6) and chemokine (CXCL10/IP-10; CXCL1/KC) levels. It was shown that AC increased OAS1-А production and significantly decreased viral replication in vitro . Increased IFNs expression together with reduced neutrophils/lymphocytes recruitment and correlated IL-4/IL-6 declination was demonstrated for Ergoferon in vivo . However, there was no effect on examined chemokines. We conclude that AC and Ergoferon possess effects against RV infection and may have potential as novel therapies against RV-induced exacerbations of asthma. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results